New Oncologic Drugs from 2008 to 2023—Differences in Approval and Access between the United States, Europe and Brazil

Introduction: Advancements in oncology have revolutionized cancer treatment, with new drugs being approved at different rates worldwide. Our objective was to evaluate the approval of new oncological drugs for solid tumors by the Food and Drug Administration (FDA), the European Medicines Agency (EMA)...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Rafael Balsini Barreto, Andressa Moretti Izidoro, Mario Henrique Furlanetto Miranda
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2024-08-01
coleção:	Current Oncology
Assuntos:	Agência Nacional de Vigilância Sanitária (ANVISA) Food and Drug Administration (FDA) European Medicines Agency (EMA) regulatory review times cancer drugs drug approval
Acesso em linha:	https://www.mdpi.com/1718-7729/31/8/332
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!